Medical/Pharmaceuticals

Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)

CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study of its potential first-in-class innovative ADC ...

2025-04-21 20:10 4065

UK Clinical Study Finds Sky Labs' Smart Ring 'CART-I' More Sensitive Than Apple Watch for AFib Detection

* Published in the international journal Heart Rhythm O2, the clinical study demonstrates that CART-I achieved 84.6% sensitivity – higher than Apple Watch's 69.1% * Sky Labs also recognized with Korea's top tech honor: IR52 Jang Young-sil Award – Prime Minister's Award SEOUL, South Korea, Ap...

2025-04-21 20:00 2572

INTCO Medical Launches New Syntex™ Synthetic Disposable Latex Gloves Featuring Breakthrough Performance Beyond Natural Latex

ZIBO, China, April 21, 2025 /PRNewswire/ -- INTCO Medical ("INTCO" or "the Company"), the world's leading manufacturer of disposable gloves, has announced the global launch of its exclusive patentedSyntex™ Synthetic Disposable Latex Gloves  product. Breaki...

2025-04-21 19:15 2670

Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025

ALAMEDA, Calif. and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will be featured at the American Associatio...

2025-04-21 19:00 2375

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved byChi...

2025-04-21 19:00 3600

Connecting Care With Clicks Announces Partnership with Prince Court Medical Center and 8 CPD Points for HCPs

KUALA LUMPUR, Malaysia, April 21, 2025 /PRNewswire/ -- Ahead of Connecting Care With Clicks 2025, Medical Channel Asia (MCA) has unveiled an expanded speaker lineup and announced Prince Court Medical Centre as the event's official Healthcare Professional (HCP) En...

2025-04-21 17:42 2765

DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies

SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumor antigen-specific anti...

2025-04-21 15:35 2431

Asia's First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring

A landmark study recently published in March 2025 by JCO Oncology Advances, demonstrates the potential ofK-TRACKTM in monitoring treatment response and assessing recurrence risk among 623 Solid-Tumor Patients of six cancer types (lung, colorectal, bre...

2025-04-19 19:45 6109

Innovation and Collaboration: Advancing China's Blood Purification Industry

LIUYANG, China, April 19, 2025 /PRNewswire/ -- On April 19, 2025, the Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang,Hunan, for its annual conference, themed "Synergy and Endless Innovation." This pivotal event united ...

2025-04-19 14:30 4378

Declaration on longevity and precision medicine launched at Abu Dhabi Global Health Week

* Establishing actionable frameworks to advance precision medicine and longevity science * The declaration highlights the impact longevity and precision medicine can have on supporting healthy communities, and engages leaders to work towards actionable solutions, drive consensus among global ...

2025-04-19 01:12 4487

Declaration on longevity and precision medicine launched at Abu Dhabi Global Health Week

* Establishing actionable frameworks to advance precision medicine and longevity science * The declaration highlights the impact longevity and precision medicine can have on supporting healthy communities, and engages leaders to work towards actionable solutions, drive consensus among global ...

2025-04-19 00:36 4308

Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch

SHANGHAI, April 18, 2025 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2024 Annual Report, highlighting a bold and determined journey forward. With a specialty pharma strategy and operational efficiency, the company exceeded its commercialization targets and advanced its innovative p...

2025-04-18 22:10 4109

Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the tre...

2025-04-18 19:39 3683

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

-          The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors -          Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% -          As the company's largest operational single-use bioreactor...

2025-04-18 14:30 4977

VISTA Eye Specialist and Tzu Chi Malaysia Continue Their Mission to Restore Sight for Underprivileged

PETALING JAYA, Malaysia, April 18, 2025 /PRNewswire/ -- In a heartfelt continuation of their mission to serve the underserved,VISTA Eye Specialist (VISTA) andTzu Chi Malaysia (Tzu Chi) have once again partnered to restore sight for the underprivileged through their second100 Cataract Surgery Prog...

2025-04-18 08:00 3133

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

Highlights * Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or64Cu) isotope. * The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capaci...

2025-04-17 21:01 3276

ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone

Showcasing at ASCRS 2025: * More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons...

2025-04-17 21:00 2735

Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025

* CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World Orphan Drug CongressUSA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum's Disease Treatment. * The Phase 2 topline results met all primary and secondary endpoints, wit...

2025-04-17 18:34 3238

Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases

MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the...

2025-04-17 18:00 2938

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

SHANGHAI, April 17, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day themed "Collaborate to Create," gathering senior executives, experts, and industry leaders to discuss R&D advances, strategic planning, and cutting-edge therapies. The event attracted hundreds from academia, i...

2025-04-17 16:07 5250
1 ... 121122123124125126127 ... 646